Sirolimus therapy for fetal cardiac rhabdomyoma in a pregnant woman with tuberous sclerosis
10.5468/ogs.2019.62.4.280
- Author:
Hyea PARK
1
;
Chi Son CHANG
;
Suk Joo CHOI
;
Soo young OH
;
Cheong Rae ROH
Author Information
1. Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. crroh@skku.edu
- Publication Type:Case Report
- Keywords:
Sirolimus;
Cardiac tumor;
Rhabdomyoma;
Tuberous sclerosis;
Fetal therapy
- MeSH:
Female;
Fetal Therapies;
Heart Neoplasms;
Hemodynamics;
Humans;
Mothers;
Organ Transplantation;
Parturition;
Pregnancy;
Pregnant Women;
Rhabdomyoma;
Sirolimus;
Transplants;
Tuberous Sclerosis
- From:Obstetrics & Gynecology Science
2019;62(4):280-284
- CountryRepublic of Korea
- Language:English
-
Abstract:
Rhabdomyoma is the most common fetal cardiac tumor, and its development is related to tuberous sclerosis. Fetal cardiac rhabdomyomas often spontaneously regress in utero or after birth, but large tumors can cause hemodynamic obstruction. Sirolimus, a mammalian target of rapamycin (mTOR) inhibitor, has been used as an immunosuppressant after organ transplantation. The mTOR inhibitors are well-known to have anti-tumor activity, and they have been used for the treatment of patients with tuberous sclerosis. In the current case, fetal cardiac rhabdomyoma was completely resolved in utero during oral sirolimus treatment in the mother with tuberous sclerosis. This case shows that oral sirolimus therapy in pregnancy may be a treatment for multiple or large fetal cardiac rhabdomyomas.
